Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute ischemic stroke~* Informed consent~* Age between 18 and 85 years~* Treatment can be initiated within 3 to 9 hours after the onset of stroke symptoms~* NIHSS Score of 4 to 24~* Vessel occlusion or high-grade stenosis on MRI or CTA in proximal cerebral arteries~Exclusion Criteria:~* Pre-stroke mRS \>1~* Previous exposure to desmoteplase~* Extensive early infarction on MRI or CT in any affected area~* Imaging evidence of ICH or SAH; AV malformation; cerebral aneurysm; or cerebral neoplasm~* Internal carotid artery occlusion on the side of the stroke lesion~* Treatment with heparin in the past 48 hours and a prolonged partial thromboplastin time~* Treatment with oral anticoagulants and a prolonged prothrombin time~* Treatment with glycoprotein IIb - IIIa inhibitors within the past 72 hours. Use of single agent oral platelet inhibitors is permitted~* Treatment with a thrombolytic agent within the past 72 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Desmoteplase (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).